Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 151
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 151
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 129
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 15
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 11
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 59
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 44
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Yingxu Fang, Jiaxing Wang, Min Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11454-11477
Closed Access | Times Cited: 44
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 38
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Donghuan Sun, Jing Zhang, Guoqiang Dong, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14276-14288
Closed Access | Times Cited: 36
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 32
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 27
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 25
Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
Xingyu Wang, Benoı̂t Gigant, Xi Zheng, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 8
Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD+
Junfei Cheng, Jing Zhang, Shipeng He, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 12
Closed Access | Times Cited: 6
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Targeting intracellular cancer proteins with tumor‐microenvironment‐responsive bispecific nanobody‐PROTACs for enhanced therapeutic efficacy
Changping Deng, Jiacheng Ma, Yuping Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
PROTAC technology for prostate cancer treatment
Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Si Chen, Xiang Li, Yinghua Li, et al.
Theranostics (2022) Vol. 12, Iss. 15, pp. 6665-6681
Open Access | Times Cited: 29
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 27
Nucleic-Acid-Based Targeted Degradation in Drug Discovery
Wei Wang, Shipeng He, Guoqiang Dong, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10217-10232
Closed Access | Times Cited: 26
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance
Huanjie Zhu, Jin Wang, Qingqing Zhang, et al.
Pharmacology & Therapeutics (2023) Vol. 244, pp. 108371-108371
Closed Access | Times Cited: 15
What is the future of click chemistry in drug discovery and development?
Ana Carolina Amorim Orrico, Anthony J. Burke
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 3, pp. 267-280
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top